Evidence map›Paper›PMID 34954640›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2022

Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort.

Sonsoles Salto-Alejandre, Zaira R Palacios-Baena, José Ramón Arribas, Juan Berenguer, Jordi Carratalà, Inmaculada Jarrín, Pablo Ryan, Marta de Miguel-Montero, Jesús Rodríguez-Baño, Jerónimo Pachón and 1 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Sonsoles Salto-AlejandreUnit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain; Institute of Biomedicine of Seville, Virgen del Rocío and Virgen Macarena University Hospitals/CSIC/University of Seville, Seville, Spain.
Zaira R Palacios-BaenaInstitute of Biomedicine of Seville, Virgen del Rocío and Virgen Macarena University Hospitals/CSIC/University of Seville, Seville, Spain; Unit of Infectious Diseases and Microbiology, University Hospital Virgen Macarena, Seville, Spain; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
José Ramón ArribasCIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, Service of Internal Medicine, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; Instituto de Investigación Hospital Universitario La Paz, Madrid, Spain.
Juan BerenguerInstituto de Investigación Hospital Universitario La Paz, Madrid, Spain; Service of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Jordi CarratalàCIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; Service of Infectious Diseases, Hospital Universitario de Bellvitge, Barcelona, Spain; Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain.
Inmaculada JarrínCIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
Pablo RyanInstituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Service of Internal Medicine, Hospital Universitario Infanta Leonor, Madrid, Spain; Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Marta de Miguel-MonteroFundación SEIMC/GeSIDA, Madrid, Spain.
Jesús Rodríguez-BañoInstitute of Biomedicine of Seville, Virgen del Rocío and Virgen Macarena University Hospitals/CSIC/University of Seville, Seville, Spain; Unit of Infectious Diseases and Microbiology, University Hospital Virgen Macarena, Seville, Spain; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; Department of Medicine, Universidad de Sevilla, Seville, Spain. Electronic address: jesusrb@us.es.
Jerónimo PachónUnit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain; Institute of Biomedicine of Seville, Virgen del Rocío and Virgen Macarena University Hospitals/CSIC/University of Seville, Seville, Spain; Department of Medicine, Universidad de Sevilla, Seville, Spain. Electronic address: pachon@us.es.
COVID-19@Spain Study Group
Instituto de Salud Carlos III · ESHospital Universitario La Paz · ESInstituto de Biomedicina de Sevilla · ESFundación Seimc-Gesida · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterferon-β is an attractive drug for repurposing and use in the treatment of COVID-19, based on its in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was to analyze the impact of early interferon-β treatment in patients admitted with COVID-19 during the first wave of the pandemic.

methodsThis post hoc analysis of a COVID-19@Spain multicenter cohort included 3808 consecutive adult patients hospitalized with COVID-19 from 1 January to 17 March 2020. The primary endpoint was 30-day all-cause mortality, and the main exposure of interest was subcutaneous administration of interferon-β, defined as early if started ≤ 3 days from admission. Multivariate logistic and Cox regression analyses were conducted to identify the associations of different variables with receiving early interferon-β therapy and to assess its impact on 30-day mortality. A propensity score was calculated and used to both control for confounders and perform a matched cohort analysis.

resultsOverall, 683 patients (17.9%) received early interferon-β therapy. These patients were more severely ill. Adjusted HR for mortality with early interferon-β was 1.03 (95% CI, 0.82-1.30) in the overall cohort, 0.96 (0.82-1.13) in the PS-matched subcohort, and 0.89 (0.60-1.32) when interferon-β treatment was analyzed as a time-dependent variable.

conclusionsIn this multicenter cohort of admitted COVID-19 patients, receiving early interferon-β therapy after hospital admission did not show an association with lower mortality. Whether interferon-β might be useful in the earlier stages of the disease or specific subgroups of patients requires further research.

Indexed as

COVID-19 Drug TreatmentAgedAged, 80 and overAntiviral AgentsCohort StudiesCOVID-19FemaleHospitalizationHumansInjections, SubcutaneousInterferon-betaMalePrognosisRetrospective StudiesSARS-CoV-2SpainAntiviral AgentsInterferon-betaCOVID-19Interferon-βMortalitySARS-CoV-2Treatment

Identifiers

PMID34954640
PMCPMC8692085
OpenAlexW4200121793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.